ECSP23017158A - Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos - Google Patents

Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos

Info

Publication number
ECSP23017158A
ECSP23017158A ECSENADI202317158A ECDI202317158A ECSP23017158A EC SP23017158 A ECSP23017158 A EC SP23017158A EC SENADI202317158 A ECSENADI202317158 A EC SENADI202317158A EC DI202317158 A ECDI202317158 A EC DI202317158A EC SP23017158 A ECSP23017158 A EC SP23017158A
Authority
EC
Ecuador
Prior art keywords
heteroaryl
derivatives
pharmaceutical uses
substituted spiropiperidinyl
spiropiperidinyl
Prior art date
Application number
ECSENADI202317158A
Other languages
English (en)
Inventor
Gebhard Thoma
David Orain
Rudolf Wälchli
Ritesh Bhanudasji Tichkule
Andrew James Culshaw
Nancy Labbe-Giguere
Timothy Brian Hurley
David Andrew Sandham
Till Roehn
Wolfgang Miltz
Srinivasan Rajagopalan
Mallesh Bushaboina
Tajesh Patel
Xin Chen
Atwood Kim Cheung
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP23017158A publication Critical patent/ECSP23017158A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención proporciona un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo; (I) en donde R1 R2, R4 y X1 han sido definidos en la presente, a un método de elaboración de los compuestos de la invención, y a sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
ECSENADI202317158A 2020-08-14 2023-03-10 Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos ECSP23017158A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20191191 2020-08-14

Publications (1)

Publication Number Publication Date
ECSP23017158A true ECSP23017158A (es) 2023-04-28

Family

ID=72088005

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202317158A ECSP23017158A (es) 2020-08-14 2023-03-10 Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos

Country Status (20)

Country Link
US (2) US11708366B2 (es)
EP (1) EP4196478A1 (es)
JP (1) JP2023537357A (es)
KR (1) KR20230051227A (es)
CN (1) CN116157404A (es)
AR (1) AR123241A1 (es)
AU (2) AU2021325431B2 (es)
BR (1) BR112023002031A2 (es)
CA (1) CA3185469A1 (es)
CL (1) CL2023000418A1 (es)
CO (1) CO2023002940A2 (es)
CR (1) CR20230125A (es)
DO (1) DOP2023000028A (es)
EC (1) ECSP23017158A (es)
IL (1) IL299091A (es)
MX (1) MX2023001725A (es)
PE (1) PE20230855A1 (es)
TW (1) TW202220990A (es)
UY (1) UY39377A (es)
WO (1) WO2022034529A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998834A (en) 1975-03-14 1976-12-21 Janssen Pharmaceutica N.V. N-(4-piperidinyl)-n-phenylamides and -carbamates
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
KR20040038899A (ko) 2001-09-28 2004-05-08 교와 핫꼬 고교 가부시끼가이샤 수용체 길항제
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
MX2010002521A (es) 2007-09-04 2010-03-25 Biolipox Ab Compuestos bis-aromaticos utiles en el tratamiento de inflamacion.
CN102762567A (zh) 2009-12-21 2012-10-31 诺瓦提斯公司 作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类
EP2545036A1 (en) * 2010-03-12 2013-01-16 Biolipox AB Bis aromatic compounds for use as ltc4 synthase inhibitors
NZ627709A (en) 2010-06-23 2014-12-24 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
CA2807051A1 (en) 2010-08-10 2012-02-16 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
EA023876B1 (ru) 2011-03-14 2016-07-29 Бёрингер Ингельхайм Интернациональ Гмбх Бензодиоксановые ингибиторы продуцирования лейкотриена
CN103814016B (zh) 2011-06-10 2017-03-08 默克专利有限公司 生产具有btk抑制活性的嘧啶和吡啶化合物的组合物和方法
JP5987220B2 (ja) 2011-07-19 2016-09-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエンａ４ヒドロラーゼの阻害剤としてのアリールピラゾールエーテル
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
DK2786996T3 (en) 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
JP6080226B2 (ja) 2012-03-06 2017-02-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン
US8946203B2 (en) 2012-03-06 2015-02-03 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
US9403830B2 (en) 2012-07-17 2016-08-02 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
US9266895B2 (en) 2012-09-10 2016-02-23 Principia Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
CN104955826B (zh) 2013-02-04 2019-05-31 默克专利股份公司 可用于治疗神经学疾病和病症的螺-喹唑酮衍生物
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EP2968359B1 (en) 2013-03-12 2021-01-20 Celltaxis, LLC Methods of inhibiting leukotriene a4 hydrolase
KR20150127245A (ko) 2013-03-14 2015-11-16 켈탁시스, 인코퍼레이티드 류코트라이엔 a4 가수분해효소의 저해제
JP6562898B2 (ja) 2013-03-14 2019-08-21 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
DK2989106T3 (en) 2013-04-25 2017-03-20 Beigene Ltd CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS
US9303018B2 (en) 2013-07-15 2016-04-05 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
EP3022194B1 (en) 2013-07-15 2017-05-17 Boehringer Ingelheim International GmbH Inhibitors of leukotriene production
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3076974A1 (en) 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
MX2016008247A (es) 2013-12-20 2016-10-21 Novartis Ag Derivados de acido heteroaril butanoico como inhibidores de lta4h.
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
SG10201903578VA (en) 2014-10-24 2019-05-30 Bristol Myers Squibb Co Indole carboxamides compounds useful as kinase inhibitors
CA2965741C (en) 2014-11-03 2022-05-17 Iomet Pharma Ltd Pharmaceutical compound
JP2017535566A (ja) * 2014-11-21 2017-11-30 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 疼痛に対する多様な活性を有する１，９−ジアザスピロウンデカン化合物
KR102524212B1 (ko) 2014-12-24 2023-04-21 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 부위 특이적 투여
GB201507753D0 (en) * 2015-05-06 2015-06-17 Biolipox Ab New compounds and uses
ES2878030T3 (es) 2015-06-03 2021-11-18 Principia Biopharma Inc Inhibidores de tirosina cinasa
WO2016201280A1 (en) 2015-06-10 2016-12-15 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
US10533011B2 (en) 2015-10-09 2020-01-14 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
RU2022100782A (ru) 2015-11-04 2022-02-03 Мерк Патент Гмбх Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
RU2728827C2 (ru) 2016-01-05 2020-07-31 Цзянсу Хэнжуй Медицин Ко., Лтд. Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения
BR112018077503A2 (pt) 2016-06-29 2019-04-09 Principia Biopharma Inc. formulações de liberação modificada de 2-[3-[4-amino-3-(2-fluoro-4- fenoxi-fenil)pirazolo [3,4-d]pirimidin-1-il]piperidino-1- carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il] pent-2-enenitrila
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers

Also Published As

Publication number Publication date
US20240043425A1 (en) 2024-02-08
UY39377A (es) 2022-03-31
AU2021325431B2 (en) 2024-01-18
US11708366B2 (en) 2023-07-25
CL2023000418A1 (es) 2023-09-29
CR20230125A (es) 2023-05-11
US20220048909A1 (en) 2022-02-17
BR112023002031A2 (pt) 2023-03-07
MX2023001725A (es) 2023-02-22
TW202220990A (zh) 2022-06-01
CA3185469A1 (en) 2022-02-17
DOP2023000028A (es) 2023-03-15
IL299091A (en) 2023-02-01
AU2021325431A1 (en) 2023-01-19
CN116157404A (zh) 2023-05-23
CO2023002940A2 (es) 2023-03-17
KR20230051227A (ko) 2023-04-17
JP2023537357A (ja) 2023-08-31
AU2024200054A1 (en) 2024-01-25
WO2022034529A1 (en) 2022-02-17
AR123241A1 (es) 2022-11-09
EP4196478A1 (en) 2023-06-21
PE20230855A1 (es) 2023-05-29

Similar Documents

Publication Publication Date Title
ECSP22071009A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CO2022016323A2 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
AR087046A2 (es) Compuestos derivados de 4-oxoquinolina
PA8591701A1 (es) Derivados de pirrolopirimidina
CR20120237A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
ECSP23017158A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
PE20040706A1 (es) Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana
AR125594A1 (es) Moduladores alostéricos negativos novedosos de ciclopenta[c]pirrol de nr2b
EA202192111A1 (ru) Новые тритерпеновые производные в качестве ингибиторов вич
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CL2022002490A1 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
UY39722A (es) Nuevos derivados de heteroaril aminopropanol
AR124982A1 (es) Macrociclos y sus usos
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
AR124136A1 (es) Nuevos compuestos orgánicos
AR126834A1 (es) Profármacos y derivados de psilocina y usos de estos
CL2022001367A1 (es) Derivados macrocíclicos de panteteína y usos de los mismos